Invitation to presentation of Mendus’ year-end report for 2023

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session.

Listen to the presentation webcast: https://ir.financialhearings.com/mendus-q4-2023

Please send any questions ahead of the presentation to [email protected]

For more information, please contact:
Erik Manting, CEO
E-mail: [email protected]

About Mendus AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

• 20240209 Mendus 4Q 2023 invite ENG

You May Also Be Interested In

• At UN General Assembly, Global Autism Advocacy Coalition launches new initiatives to accelerate autism action worldwide
• UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million
• BNB Price Prediction: BNB Holds Near $774 as Remittix Sets a $0.46 Final Stage Above Its $0.21 Entry